HHS Announces Major Leadership Changes
The US Department of Health and Human Services (HHS) is undergoing a significant leadership restructuring, with several key departures and new appointments reshaping the agency. These changes come after nearly a year under Secretary Robert F. Kennedy Jr. and signal a strategic realignment ahead of the 2026 midterm elections. Officials and health policy observers are closely watching the impact these transitions may have on public health priorities across the country.
Jim O’Neill Exits CDC Director Role
Jim O’Neill, the Acting Director of the Centers for Disease Control and Prevention (CDC) and Deputy Health Secretary, is departing his current role. Kennedy appointed O’Neill to lead the CDC in August 2025 following the controversial dismissal of former director Susan Monarez, PhD. General Counsel Mike Stuart, JD, is also stepping down from his position. Both officials are reportedly transitioning to other roles within the broader federal administration rather than leaving government service entirely.
O’Neill Oversaw Controversial Vaccine Schedule Changes
O’Neill was never confirmed by the Senate, yet he served as one of the most visible champions of Kennedy’s “Make America Healthy Again” (MAHA) movement within the CDC. Under his leadership, the CDC announced significant and widely debated changes to the recommended childhood vaccine schedule. These updates generated strong criticism from medical professionals and public health advocates, who expressed concern over the scientific basis and potential consequences for childhood immunization rates nationwide.
Chris Klomp Takes Over HHS Operations
Secretary Kennedy announced that Chris Klomp, previously the deputy administrator of the Centers for Medicare and Medicaid Services (CMS), will now oversee all HHS operations. Klomp played a central role in the Trump administration’s efforts to reduce prescription drug prices, making him a trusted figure in health care affordability efforts. Anonymous sources cited by Politico indicate the restructuring is partly motivated by the upcoming midterms, with the White House recognizing that health care costs remain a top concern for American voters.
Kennedy addressed the changes directly, stating: “We are restoring accountability, challenging entrenched interests, and putting the health of the American people first. I am proud to elevate battle-tested, principled leaders onto my immediate team—individuals with the courage and experience to help us move faster and go further as we work to Make America Healthy Again.”
NIH Faces Leadership Vacuum Across Institutions
In a related development reported by NBC News, 16 of the 27 institutions comprising the National Institutes of Health (NIH) currently lack permanent directors. The vacancies stem from a combination of resignations, retirements, and terminations that have occurred under NIH Director Jay Bhattacharya, MD. HHS spokesperson Andrew Nixon confirmed the vacancies but emphasized the agency’s commitment to filling all positions with highly qualified individuals focused on addressing chronic disease and maintaining scientific standards.
NIH has operated as a nonpartisan scientific institution for 139 years, with directors historically serving across multiple presidential administrations regardless of political affiliation.
Experts Raise Concerns Over MAHA Influence
Current NIH staff and scientific observers have voiced serious concern that open leadership positions may be filled with appointees aligned with Kennedy’s MAHA agenda rather than traditional institutional priorities. Shiv Prasad, PhD, a scientific review officer at NIH, told NBC: “I’m not confident that their appointments will be with the institute’s mission in mind. I think you’re just there to be compliant with whatever the HHS secretary wants done.”
These concerns reflect a broader anxiety within the federal health research community about the long-term independence and credibility of institutions like the NIH and CDC during a period of unprecedented leadership turnover.
